US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by VBI Vaccines Inc.

< Previous 1 2 3 Next >
News headline image
VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations
From VBI Vaccines Inc.
Via Business Wire
News headline image
VBI Vaccines Provides an Update on its Restructuring Proceedings
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces Results of Annual General Meeting
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Reports First Quarter 2024 Financial Results
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Reports Full Year 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Reports Third Quarter 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Reports Second Quarter 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces Results of Annual General Meeting
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Announces Poster Presentation at EASL 2023
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Reports First Quarter 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
News headline image
VBI Vaccines Appoints Vaughn Himes to Board of Directors
From VBI Vaccines Inc.
Via Business Wire
Tickers VBIV
< Previous 1 2 3 Next >